Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Spironolactone-induced hepatitis.

K E Thai1, R D Sinclair

  • 1Department of Medicine (Dermatology), The University of Melbourne, St Vincent's Hospital, Melbourne, Victoria, Australia.

The Australasian Journal of Dermatology
|August 8, 2001
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Excision biopsy in a patient with suspected local anaesthetic allergy: use of 0.9% saline with benzyl alcohol as local anaesthesia.

Clinical and experimental dermatology·2012
Same author

Bioprospecting keratinous materials.

International journal of trichology·2010
Same author

Management of primary cicatricial alopecias: options for treatment.

The British journal of dermatology·2008
Same author

Disappearance of pili annulati following an episode of alopecia areata.

Clinical and experimental dermatology·2002
Same author

Loose anagen syndrome as a severity factor for trichotillomania.

The British journal of dermatology·2002
Same author

Keratosis pilaris and hereditary koilonychia without monilethrix.

Journal of the American Academy of Dermatology·2001
Same journal

The Rintala Advanced Modification (RAM) Flap: A Novel Technique for Off-Centre Nasal Reconstruction.

The Australasian journal of dermatology·2026
Same journal

Immunotherapy for Melanoma: A Concise Clinical Review for Australasian Practice.

The Australasian journal of dermatology·2026
Same journal

Pyoderma Gangrenosum: Association of Ulcer Size With Clinical Characteristics and Healing Outcomes.

The Australasian journal of dermatology·2026
Same journal

Recurrence Rates of Incompletely Excised Primary Basal Cell Carcinoma Treated With Mohs Micrographic Surgery and Radiotherapy.

The Australasian journal of dermatology·2026
Same journal

A Retrospective Cohort Study of Extended Dupilumab Dosing in Atopic Dermatitis: Assessing the Impact on Disease Severity and Understanding Characteristics Linked to Successful Dose Extension.

The Australasian journal of dermatology·2026
Same journal

Exploring and Comparing the Psychosocial Impacts of Vitiligo on a Broader Scale: An International Survey via the Use of Social Media.

The Australasian journal of dermatology·2026
See all related articles

Spironolactone, commonly used for hair loss, can cause drug-induced hepatitis. This case highlights the importance of monitoring liver function during spironolactone treatment, as symptoms resolved upon drug withdrawal.

Area of Science:

  • Hepatology
  • Pharmacology

Background:

  • Spironolactone is widely prescribed for various medical conditions.
  • Its established indications and side effect profile are well-documented.
  • Androgenetic alopecia is a common condition for which spironolactone is sometimes used off-label.

Observation:

  • A 50-year-old woman developed symptoms of liver injury six weeks after starting spironolactone for androgenetic alopecia.
  • She presented with pruritus (itching) but no jaundice or icterus.
  • Initial liver function tests revealed elevated bilirubin and liver enzymes.

Findings:

  • The patient's symptoms and abnormal liver function tests resolved after discontinuing spironolactone.
  • This case represents a rare instance of spironolactone-induced hepatitis.

Related Experiment Videos

  • Only one prior report of spironolactone-induced hepatitis has been documented.

    • Implications:

    • This case underscores the potential for spironolactone to cause drug-induced liver injury, even in rare circumstances.
    • Healthcare providers should consider monitoring liver function in patients on long-term spironolactone therapy, particularly those with risk factors.
    • Further investigation into the mechanisms of spironolactone-induced hepatotoxicity may be warranted.